News
NAMSW
11.78
0.00%
0.00
NewAmsterdam Pharma: Potential Coupled With Uncertainty
Seeking Alpha · 3d ago
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and NewAmsterdam Pharma Company (NAMS)
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: NewAmsterdam Pharma Company (NAMS), Merck & Company (MRK) and Royalty Pharma (RPRX)
TipRanks · 3d ago
NewAmsterdam Pharma Price Target Maintained With a $52.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS)
TipRanks · 3d ago
HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target
Benzinga · 3d ago
Biggest stock movers Tuesday: ZIM, NVS, and more
Seeking Alpha · 3d ago
Novartis drops 13% on trial failure, dragging Dyne and Sarepta
Seeking Alpha · 3d ago
Weekly Report: what happened at NAMS last week (0831-0904)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 09/04 21:06
Mid-cap healthcare stocks ranked by quant ratings after earnings season
Seeking Alpha · 09/01 14:15
Weekly Report: what happened at NAMS last week (0824-0828)?
Weekly Report · 08/31 10:12
Top Executive Makes Major Move With NewAmsterdam Pharma Stock
TipRanks · 08/26 02:03
Weekly Report: what happened at NAMS last week (0817-0821)?
Weekly Report · 08/24 10:12
Weekly Report: what happened at NAMS last week (0810-0814)?
Weekly Report · 08/17 10:13
Weekly Report: what happened at NAMS last week (0803-0807)?
Weekly Report · 08/10 10:09
Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)
TipRanks · 08/07 21:55
NewAmsterdam Pharma Is Maintained at Outperform by RBC Capital
Dow Jones · 08/06 17:55
NewAmsterdam Pharma Price Target Cut to $50.00/Share From $51.00 by RBC Capital
Dow Jones · 08/06 17:55
More
Webull provides a variety of real-time NAMSW stock news. You can receive the latest news about NewAmsterdam Pha through multiple platforms. This information may help you make smarter investment decisions.
About NAMSW
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.